Skip to main content
. 2021 Aug 3;5(9):e10530. doi: 10.1002/jbm4.10530

Fig. 9.

Fig. 9

Anti‐TGF‐β antibody 1D11 inhibits hyperactivation of osteoclasts in osteogenesis imperfecta (OI) femoral trabecular bone at three‐times weekly dosing for 12 weeks, 5 mg/kg ip. μCT femur n = 8, 5, and 5 for groups 1–3, respectively. (A) OI +13C4 exhibits increased TRACP staining relative to WT +13C4, and this increase is corrected to WT levels with 1D11 treatment. (B) Histomorphometry in OI + 13C4 bone exhibits a fivefold increase in N.Oc./BS relative to WT + 13C4, and this increase is corrected with 1D11 treatment to WT levels. Mean ± SD and asterisk(s) denote statistically significant difference compared with OI 13C4. c p < 0.001. N.Oc./BS = the ratio of the number of osteoclasts relative to bone surface area; TRACP = tartrate‐resistant acid phosphatase .